Large-scale hormone replacement therapy and life expectancy: Results from an international comparison among European and North American populations

American Journal of Public Health

Volumn 90, Issue 9, 2000, Pages 1397-1402

  Panico, S ^a   Galasso, R ^a   Celentano, E ^a   Ciardullo, A V ^a   Frova, L ^a   Capocaccia, R ^a   Trevisan, M ^a   Berrino, F ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER MORTALITY; COLON CANCER; ENDOMETRIUM CANCER; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FEMALE; FRACTURE; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MENOPAUSE; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME;

EID: 0033851780     PISSN: 00900036     EISSN: None     Source Type: Journal    
DOI: 10.2105/AJPH.90.9.1397     Document Type: Article

References (46)

1. Estrogen and coronary heart disease
2. The primary prevention of myocardial infarction
3. Hormone therapy to prevent disease and prolong life in postmenopausal women
4. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence
5. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease
6. HRT: An analysis of benefits, risks and costs
7. A review of the association of estrogens and progestin with cardiovascular disease in postmenopausal women
8. Patient-specific decisions about hormone replacement therapy in postmenopausal women
9. Ethinil estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in post-menopausal women
10. Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease
11. 17 Betaestradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease
12. Design of the Women's Health Initiative clinical trial and observational study
13. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women
14. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 without breast cancer
15. Timing of postmenopausal estrogen for optimal density: The Rancho Bernardo Study
16. Coronary heart disease: Reducing the risk. International Task Force
17. Use of hormone replacement therapy Hormone replacement therapy may not always be fight choice to prevent cardiovascular disease
18. Age, period, cohort and early mortality: An analysis of adult mortality in Italy
19. Hormone replacement therapy and endometrial cancer risk: A meta-analysis
20. Estimating the completeness of prevalence based on cancer registry data
21. Cardioprotective effect of hormone replacement therapy in postmenopausal women: Is the evidence biased?
22. Prior to use of estrogen replacement therapy, are users healthier than non-users?
23. The waning effect of post-menopausal estrogen therapy on osteoporosis
24. Impact of post-menopausal hormone therapy on cardiovascular events and cancer: Pooled data from clinical trials
25. Impact of postmenopausal hormone therapy on cardiovascular events and cancer. More women are excluded from treatment arm of such trials because of cardiovascular events
26. Impact of postmenopausal hormone therapy on cardiovascular events and cancer. Search for studies was limited
27. Impact of postmenopausal hormone therapy on cardiovascular events and cancel Paper's main conclusion is no longer justified when data from all trials are considered
28. Impact of postmenopausal hormone therapy on cardiovascular events and cancer. Combining thromboembolic events with cardiovascular events does not support odds ratio of 0.7
29. Impact of postmenopausal hormone therapy on cardiovascular events and cancer. Inclusion of one particular study was inappropriate
30. Impact of postmenopausal hormone therapy on cardiovascular events and cancer. Study's conclusions were incorrect
31. Hormone replacement therapy and heart disease prevention
32. Can selection bias explain the cardiovascular benefits of estrogen replacement therapy?
33. Health prior to hormone use: Reply to Goldstein
34. Hormone replacement therapy and risk of non-fatal stroke
35. Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States
36. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy - Long-term follow-up of a Swedish cohort
37. Postmenopausal hormone therapy and mortality
38. Estrogen replacement therapy and breast cancer survival in a large screening study
39. Hormone replacement therapy and early clinical appearance of low grade breast cancer
40. Hormone replacement therapy and breast cancer mortality in Swedish women: Results after adjustment for 'healthy drug-user' effect
41. Prognostic characteristics in breast cancer after hormone replacement therapy
42. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy
43. The relationship between breast cancer survival and prior postmenopausal estrogen use
44. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women